CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, announced that President
and CEO Steven A. Kriegsman and Vice President of Business Development
David J. Haen will present at the 2013 Leerink Swann Global Healthcare
Conference on Thursday, February 14, 2013, at 1:30 p.m. Eastern time
(10:30 a.m. Pacific time). The conference is being held at the
Waldorf=Astoria Hotel in New York City.
A webcast of the presentation will be available on the Company’s website
at http://cytrx.com/investors/presentations.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company specializing in oncology. The CytRx oncology pipeline includes
two programs in clinical development for cancer indications: aldoxorubicin
(formerly known as INNO-206) and tamibarotene.
With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has
initiated an international Phase 2b clinical trial as a treatment for
soft tissue sarcomas, has completed its Phase 1b/2 clinical trial
primarily in the same indication, and has initiated a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors
and a Phase 1b study of aldoxorubicin in combination with doxorubicin in
patients with advanced solid tumors. The Company has held a positive
meeting with the FDA to discuss a potential Phase 3 pivotal trial with
aldoxorubicin as a therapy for patients with soft tissue sarcomas whose
tumors have progressed following treatment with chemotherapy, and has
submitted a special protocol assessment related to this trial.
Tamibarotene is being tested in a double-blind, placebo-controlled,
international Phase 2b clinical trial in patients with non-small-cell
lung cancer. The Company completed its evaluation of a third drug
candidate, bafetinib,
in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about CytRx Corporation,
visit www.cytrx.com.
